Search
for
Sort by
Research 151–180 of 1000+
- Re: Can Long-Term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?
- Assessment of Female Sexual Dysfunction in Patients with Premenopausal Female Pattern Hair Loss
- High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Advancements in Drug Repurposing: Examples in Psychiatric Medications
- FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women
- Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir
- Suspected adverse reactions to medications and food supplements containing <i>Serenoa repens</i>: A worldwide analysis of pharmacovigilance and phytovigilance spontaneous reports
- Drug Repurposing of Voglibose, a Diabetes Medication for Skin Health
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Vitamin D Adequacy Conditions the Prolactin-Suppressive Effect of Metformin in Men Receiving Prolactin-Elevating Medications
- 705 Influence of 5a-Reductase Inhibitor (5-ARI) Usage on the Reproductive Function of Married Men
- A review of the treatment of male pattern hair loss
- Current Literature Review
- The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
- Farmácia Sanches - Leiria e nos Serviços Farmacêuticos do Hospital Lusíadas - Porto
- Investigation of the Plausibility of 5-Alpha-Reductase Inhibitor Syndrome
- An (Ir)reversible Affection of the Sexual Sphere: A Case Report
- Direct-to-Consumer Teledermatology for Male Androgenetic Alopecia: Narrative Review
- Digital health platforms expand access and improve care for male androgenetic alopecia
- Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
- The connection of 5-alpha reductase inhibitors to the development of depression
- Battling a receding tide: Treatment for androgenic alopecia
- Biomaterials for Treatment of Baldness
- Repurposing existing drugs for COVID-19: an endocrinology perspective
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- A Gender Hypothesis of sex disparities in adverse drug events
- European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity
- A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection
- Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness?
- Post-finasteride syndrome – does it really exist?